International Journal of Drug Regulatory Affairs

An Analytical Study of Selected Bulk Drug Manufacturers in Andhra Pradesh and Telangana: SEZ Status, Regulatory Framework, Compliance, Oversight, and Workforce Welfare and Safety

2026-06-16T13:47:28-04:00

Introduction: India’s bulk drug manufacturing industry has witnessed rapid growth over the past two decades, driven by supportive government policies, financial incentives, and regulatory reforms such as the Special Economic Zones (SEZ) Act 2005 and Rules 2006. Encouraged by these initiatives, several major pharmaceutical companies established manufacturing units across Andhra Pradesh and Telangana, particularly in industrial clusters and SEZs. Although this expansion significantly strengthened India’s pharmaceutical sector, it was also accompanied by multiple industrial accidents resulting in loss of lives and raising concerns about workplace safety and employee welfare.

Methods: This research paper evaluates ten selected bulk drug manufacturing companies using publicly available documents, regulatory reports, and media sources. The analysis is based on four key parameters: regulatory compliance, regulatory oversight, employee welfare, and workplace safety, along with a review of reported accidents.

Results and Discussion: The findings indicate that listed pharmaceutical companies generally perform better across all evaluated criteria. In contrast, certain SEZ-based unlisted companies, including Hetero SEZ Infrastructure and Escentia, appear to show weaker commitment toward employee welfare and occupational safety.

Summary: The study emphasizes the need for stricter regulatory enforcement, regular safety audits, greater transparency, and stronger accountability to ensure safer and more sustainable growth of the bulk drug manufacturing industry in India.

Conclusion: The review highlights the growth of India’s bulk drug industry and evaluates regulatory compliance, employee welfare, and workplace safety among selected companies. It emphasizes the need for stricter regulations, regular safety audits, transparency, and stronger accountability to ensure sustainable and safe industrial development.

Application of Failure Modes and Effects Analysis (FMEA) for Conducting Multiple Risk Assessments in a New Pharmaceutical Facility

2026-06-15T12:13:56-04:00

Global pharmaceutical compliance frameworks, WHO GMP, and ICH Q9 (R1) all require the application of Quality Risk Management (QRM). Infrastructure, clean utilities, sterilization systems, environmental controls, and process equipment are all intricately integrated in recently built pharmaceutical production plants, generating a number of possible sites of failure during commissioning. Therefore, to guarantee operational robustness and regulatory compliance, a proactive and organized risk assessment strategy is crucial.

For the risk-based commissioning of a new oral solid dosage production facility, this study suggests an integrated, multi-domain application of FMEA. A group of people from different departments worked together to use FMEA in five important areas: the steps for introducing new products, the equipment used for sterilizing, the system for making pure steam, the system for making purified water, and the design and layout of the facility. ICH Q9-aligned Severity, Occurrence, and Detection score was used to identify and rank the risks. The design concept for facility lifecycle management included structured mitigation techniques.

The suggested integrated FMEA model supports ongoing GMP adherence and improved quality assurance during pharmaceutical facility implementation by providing a scalable and regulatory-aligned method for early risk identification, cross-functional cooperation, and proactive compliance management.

Conclusion: This paper demonstrates that the combination of an inter-domain application of the FMEA provides a structured and efficient approach to risk identification and reduction during commissioning of pharmaceutical facilities. It ensures enhanced operational reliability, cross-functional teamwork and continuous compliance with GMPs, by complying with ICH Q9. Altogether, it can be concluded that the model offers a versatile model of the proactive quality risk management in modern pharmaceutical manufacturing.

Comparative Analysis of Regulatory Approval Processes for Medical Devices in India and the European Union

2026-06-15T12:27:41-04:00

The regulatory approval framework for medical devices is essential to ensure safety, performance, and quality before market entry. This article presents a comparative analysis of the approval processes in India and the European Union (EU), highlighting structural and procedural differences. In India, devices are regulated under the Medical Devices Rules, 2017 by the Central Drugs Standard Control Organization (CDSCO), using a risk-based classification system with defined requirements for licensing, clinical investigation, and post-market surveillance. In contrast, the EU Medical Device Regulation (EU) 2017/745 (MDR) establishes a more comprehensive framework involving notified bodies, conformity assessment, CE marking, clinical evaluation, and stringent vigilance mechanisms. This comparison supports strategic regulatory planning and identifies opportunities for harmonization in global medical device regulation.

Conclusion: This comparative analysis of the regulatory approval processes for medical devices in India and the European Union demonstrates that both jurisdictions are grounded in risk-based regulatory philosophy, yet differ substantially in the depth, structure, and lifecycle integration of regulatory oversight.

Automated Classification of Post-Approval Changes Using Regulatory Intelligence Models

2026-06-15T12:32:46-04:00

conflicting categorizations across different countries. We processed 7,500 PACs with 47.7% minor, 48.7% moderate, and 3.7% major changes. For this study, the machine learning algorithms of Gradient Boosting, Random Forest, SVM, and Logistic Regression were trained on 16 regulatory features varying from clinical impact, quality risk, and explanation of quality scores. Gradient Boosting was found to have the highest accuracy of 87.3% for classification, surpassing traditional classification methods and minimizing discrepancies in approval times. For quality scores with high justification, approval times were reduced by 23%, and major changes took an average of 287.5 days as opposed to 156.7 days for minor changes. Such automated platforms have the potential to save 60%–75% of time spent on manual classification methods and allow real-time API connectivity with regulatory intelligence systems. The automated classification results of PACs have a vast potential for scaling up the consistency of regulations, improving approval times, and laying the foundation for global harmonization in post-approval change management.

Conclusion: The machine learning-driven classification of post-approval changes has shown good predictive capability, and the results demonstrate the achievement of reductions in the regulatory approval time. This substantiates the feasibility of the incorporation of regulatory intelligence with the use of AI systems for the achievement of harmonization

Regulatory Frameworks Governing Pharmaceutical Manufacturing Site Transfers: A Comparative Review of WHO, EMA, and US FDA Approaches

2026-06-15T12:41:16-04:00

Pharmaceutical manufacturing site transfers are critical strategic activities driven by mergers, outsourcing, and supply chain optimization, yet they carry significant risks to product quality and patient safety if not properly regulated. This review provides a comparative analysis of the regulatory frameworks governing site transfers established by the World Health Organization (WHO), the European Medicines Agency (EMA), and the United States Food and Drug Administration (FDA), contextualized within the harmonization efforts of the International Council for Harmonisation (ICH). Publicly available regulatory guidelines, including WHO Annex 7 of TRS 961, EMA Commission Regulation (EC) No 1234/2008, FDA 21 CFR Part 314.70, and ICH quality guidelines Q8-Q12, were systematically reviewed and compared. The analysis reveals that while all three bodies share the fundamental goal of ensuring product quality, safety, and efficacy during transfers, their approaches differ significantly. The WHO provides a process-oriented, knowledge-based blueprint emphasizing Technology Transfer Plans and Analytical Method Transfer. The EMA employs a legally binding, risk-based variation classification system (Type IA, IB, II) with defined procedural timelines. The FDA utilizes a tiered submission pathway (PAS, CBE-30, Annual Report) heavily influenced by facility inspection history and operational parity. Key challenges including harmonization gaps, documentation burden, inspection delays, and supply continuity risks are examined alongside strategic best practices such as early regulatory engagement, robust project management, and inspection readiness. This review concludes that a comprehensive understanding of these distinct regulatory frameworks, combined with the application of ICH principles, enables pharmaceutical companies to execute compliant and efficient global site transfers, ultimately ensuring uninterrupted delivery of safe and effective medicines to patients worldwide.

Conclusion: This review highlights the need for a well-structured regulatory strategy that ensures product quality, patient safety, and efficient global pharmaceutical site transfers.

Drug Safety of Antihypertensive Medicines Using Pharmacovigilance Data: Signal Management Through Traditional Methods Versus Process Automation

2026-06-15T12:52:02-04:00

Hypertension remains a leading etiological agent of cardiovascular morbidity and mortality worldwide, thus requiring vigorous marketing pharmacovigilance of anti-hypertensive drugs. In the current study, the conventional approaches of signal detection used manually were compared with the processing automation procedure using extensive actual data accumulated using the FDA Adverse Event Reporting System (FAERS) during the past years, especially selected representative therapeutics, amlodipine, ramipril, and minoxidil. The old paradigms were based on manual case assessments together with disproportion measures (mainly the Reporting Odds Ratio (ROR)) and supplemented with expert clinical adjudication. Conversely, the automated model used a scripted pipeline, which included data cleaning, natural-language processing, automated codification and derivation of statistical signals. A mixed system was employed, combining a pre-screening with an expert validation as a requirement.

The automated approach increased the range of detections and the efficiency of operations and, at the same time, increased sensitivity, but at the cost of a higher rate of possible false-positive indications. The hybrid scheme was the most balanced, which offered the maximum credible signal capture, better sensitivity on genuine pharmacological matters, high specificity persistence, and equal accompanying noise decrease.

These results support the idea that hybrid signal management systems, which consist of automated routine and high-volume processes with domain knowledge to make conclusive judgments, is optimal, scalable, and regulatory compliant to the current condition of pharmacovigilance, especially in resource-limited environments.

Conclusion: This comparative evaluation of the signal detection methodologies of anti-hypertensive drugs gives a clear outline of the supplementary benefits of both the traditional and automated application techniques. Hybrid models are therefore an evidence based and pragmatic step towards modern signal management especially relevant in the changing pharmacovigilance set ups of India and other regions that face similar data and resource bottlenecks.

A Comparative Study of Medical Device Regulatory Frameworks: India vs. the European Union

2026-06-15T20:45:18-04:00

The regulatory frameworks governing medical devices have become increasingly complex and crucial for ensuring patient safety and product efficacy due to rapid technical advancement and expanding international trade. This study examines the medical device regulatory frameworks of the European Union (EU) and India, focusing on device classification, approval processes, clinical evaluation, and post-market surveillance requirements. India controls medical devices under the Medical Devices Rules (IMDR), 2017 and later amendments, whereas the EU operates under the Medical Device Regulation (MDR) 2017/745 and In Vitro Diagnostic Regulation (IVDR) 2017/746.Both regions employ risk-based classification systems, according to the report, but the EU framework—which is supported by CE marking, notified authorities, and centralized databases like EUDAMED—shows a more advanced, standardized, and globally recognized regulatory structure. On the other hand, India has achieved significant progress because of digital platforms like SUGAM and centralized regulatory oversight by CDSCO; yet, problems with post-market surveillance transparency and data accessibility persist. The study concludes that while India's regulatory ecosystem is steadily strengthening, greater regulatory alignment with international standards and convergence with the EU could improve patient safety, promote innovation, and facilitate the entry of medical devices into international markets.

Conclusion: The review also explains a brief about India and EU regulatory requirement for registration of medical device and comparative data between two countries.

A Comparative Study of the Regulatory Landscape for Pre-filled Syringes (PFS) in the Philippines and Uganda

2026-06-15T21:03:44-04:00

The regulatory approval of pharmaceutical products like Pre-filled Syringes (PFS) differs significantly among various international health authorities due to the format of the dossier, the time taken to evaluate the product, and the legal requirements that must be fulfilled. This paper seeks to compare the registration procedures of the National Drug Authority (NDA) of Uganda, which follows a five-module format of the Common Technical Document (CTD), and the Food and Drug Administration (FDA) of the Philippines, which follows the ASEAN format of the Asian Common Technical Dossier (CTD) comprising four parts. Unlike the NDA of Uganda, which regulates the Ugandan market, where 90% of the drugs used are imported, the FDA of the Philippines requires a Certificate of Product Registration (CPR) to market a product.

Conclusion: Regulatory approval for pre-filled syringes varies between Uganda and the Philippines in dossier format, timelines, and legal requirements. Uganda follows a five-module CTD, while the Philippines uses the ASEAN ACTD and requires a Certificate of Product Registration.

Regulatory Lifecycle Management of Solid Oral Dosage Forms in Nigeria and Kenya

2026-06-15T21:17:14-04:00

Solid oral dosage forms (SODFs), including tablets and capsules, are the most commonly used pharmaceutical products worldwide, requiring effective regulatory oversight throughout their lifecycle to ensure quality, safety, and efficacy. This review compares the regulatory lifecycle management frameworks for SODFs in Nigeria and Kenya, focusing on pre-market authorization, post-approval variation management, pharmacovigilance, and marketing authorization renewal. Drawing on regulatory guidelines, legislative frameworks, and relevant literature, the review finds that both Nigeria’s NAFDAC and Kenya’s PPB have adopted internationally aligned regulatory approaches, including CTD-based submissions, GMP inspections, and post-marketing surveillance systems. Despite progress in regulatory maturity and regional harmonization efforts, challenges such as limited resources, regulatory backlogs, and underreporting of adverse drug reactions remain. The experiences of both countries provide valuable insights for strengthening regulatory systems and supporting effective medicine lifecycle management across Africa.

Conclusion: Nigeria and Kenya have made significant progress in aligning SODF regulatory practices with international standards across the product life cycle. However, challenges in implementation particularly in Nigeria persist while on going regional harmonization efforts present promising opportunity to strengthen regulatory efficiency and consistency in sub–Saharan Africa.

Comparative Study of CTD Modules 3, 4, and 5: Generic Drugs versus Complex Generics (Liposomal Injectables) in the United States, European Union, and Japan

2026-06-15T21:25:07-04:00

Liposomal drug delivery systems form an important branch of pharmaceutical product nanomedicine. Unlike traditional small-molecule generics, structural and physicochemical characteristics of a lipid carrier system do not only regulate the therapeutic behavior of an active pharmaceutical ingredient but also influence it. The liposomal formulations are therefore categorised as complex generics or non-biological complex drugs (NBCDs). To prove the similarity of liposomal generics and their reference products would thus require a wider range of analytical, non-clinical and clinical data in comparison with traditional generics. The current paper compares liposomal complex generics regulatory expectations in 3 major jurisdictions of the United States, the European Union, and Japan. The comparison will be made on the Common Technical Document(CTD) Modules 3, 4, and 5, which indicate, quality documentation, non-clinical evidence, and clinical evidence respectively. Regulations and peer-reviewed literature have been analyzed in order to determine variation in regulatory demands across these areas. The results show that complex generics require thorough description of physicochemical properties, biological activity as well as pharmacokinetic functioning due to the impact of nanoscale structural features on drug targeting and toxicity. Regulatory agencies vary in their scientific principles even though they have similar principles of regulation. European Union is focused on comparability in detail; Japan focuses more on mechanistic non-clinical evaluation and the United States uses a risk-based regulatory model which incorporates quality attributes and pharmacokinetic data. These regulatory differences can help pharmaceutical developers to understand before submitting liposomal complex generics to global regulations.

Conclusion: Liposomal generics require more extensive evaluation than traditional generics, including detailed structural and biological characterization. Regulatory expectations differ: Europe emphasizes analytical comparability, Japan focuses on nonclinical studies, and the US follows a risk-based approach with quality and PK data. Understanding these regional differences is essential for efficient development and successful global submissions.

Lifecycle Continuity Through Regulatory Compliance: A Comparative Evaluation of Post-Approval Change Strategies for APIs and Drug Products Under the Regulatory Frameworks of Saudi Arabia, the United States, Australia, and Eurasia

2026-06-15T21:32:31-04:00

The paper presents a parallel assessment of after-clearance change demands for drug substances between the regulatory structures of Saudi Arabia, US, Australia, and the Eurasian Economic Union. The regulatory structures that steer these changes in each area are fundamental for the upkeep of drug safety, usefulness, and standards as healthcare advances. The research strategy calls for a careful study of relevant standards, rules, and case assessments from all named realms. Key aspects such as the nature of amendments, data demands, clearance pathways, and treatment schedules are analyzed to understand the challenges of regulatory adherence. Added to that, the effect of these demands on market ventures, advancement, and access to treatments has been evaluated.

Conclusion: In conclusion, The Review also explain that this comparative analysis demonstrates that while Saudi Arabia, US, FDA, Australia, and Eurasian Economic Union regulations on API and drug product post-approval change management are all risk-based and critical to continued safety, efficacy, and quality, these regulations also vary with respect to classification, data, and timelines.

Overview of Structural Specifications and Validation of eCTD (v3.2.2): Elucidation of the General Architecture of EU Module 1 and GCC Module 1

2026-06-16T13:27:21-04:00

A comprehensive understanding of the eCTD structural specifications ensures compliance, accelerates the product approval process, and facilitates seamless interactions between pharmaceutical companies and regulatory authorities. This article provides an overview of the eCTD submission process and the scope of eCTD challenges and Module 1 (Region-Specific Administrative and Product Information). It provides an epitomisation of the eCTD structural specifications, along with an illustration of Module 2 folder naming and structure. The article outlines the general architecture of EU Module 1 and GCC Module 1, demonstrating the envelope, directory/file structures, as well as file naming conventions and formats. Additionally, it explains the stages of eCTD validation and some of the Validator tools; it also includes three practical cases illustrating common validation errors. Furthermore, it demonstrates the transition to eCTD version 4.0 and its implementation timeline across the EMA, FDA, Health Canada, and PMDA (Japan).

Conclusion: Conducting eCTD structural specifications governs the electronic submission framework to ensure seamless regulatory compliance. Module 1 (EU, GCC) demands precise adherence to regional regulatory requirements. Vigilance in preparing the eCTD and its validation process plays a quintessential role in minimizing submission errors, achieving approval, and enabling quicker access to new products.

Driving First‑Cycle ANDA Approvals Through Strategic Regulatory Planning

2026-06-16T13:01:27-04:00

Getting first-cycle approval for Abbreviated New Drug Applications (ANDAs) is crucial for generic drug sponsors, especially when quick market entry and regulatory risks are at stake. Even though the U.S. Food and Drug Administration has established clear review processes and goals under the Generic Drug User Fee Amendments (GDUFA), many ANDAs remain delayed by avoidable problems in bioequivalence, chemistry, manufacturing, and controls, labeling, and facility compliance.

This article looks at what affects first-cycle ANDA approval. It highlights the importance of making early regulatory decisions, spotting risks before filing, and keeping the team on the same page. It also covers how to prepare before and after submission, maintain quality, answer review questions, and get ready for inspections.

The article uses performance metrics and real-world examples to show how sponsors can shorten review times and improve their chances of approval. Careful planning and steady execution help organizations avoid last-minute changes and achieve more predictable, timely approvals.

Conclusion: A structured, proactive regulatory strategy significantly increases the likelihood of first-cycle ANDA approval. Early risk identification, robust submission quality, and strong cross-functional coordination help reduce review cycles and enable more predictable and timely approvals.

Comparative Analysis of Cosmetic Labelling Requirements in the United States and Japan

2026-06-19T12:04:46-04:00

Cosmetic labelling regulations serve as a fundamental mechanism to ensure consumer safety, transparency, and regulatory compliance. With the expansion of international cosmetic trade, manufacturers must comply with varying regulatory frameworks across different jurisdictions. In the United States, cosmetics are regulated by the US Food and Drug Administration under the Federal Food, Drug, and Cosmetic Act and the Fair Packaging and Labeling Act. In Japan, cosmetic products are governed by the Pharmaceuticals and Medical Devices Law administered by the Ministry of Health, Labour and Welfare. This review presents a structured comparative evaluation of cosmetic labelling requirements in both countries, focusing on mandatory label elements, ingredient declaration systems, language obligations, claims regulation, warning statements, and enforcement mechanisms. The analysis identifies major similarities and regulatory differences that impact global market entry strategies.

Conclusion: Although both regulatory systems aim to protect consumer health, the United States follows a manufacturer-responsibility and post-market surveillance model, whereas Japan adopts a more prescriptive and language-specific regulatory structure. Understanding these distinctions is essential for regulatory compliance and successful international marketing.